Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia Sep 18, 2023
Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing Sep 11, 2023
Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing Sep 5, 2023
Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update Aug 14, 2023
UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update May 4, 2023
Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update May 4, 2023
Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient Feb 28, 2023
